OvaScience Inc. (NASDAQ:OVAS) saw an uptick in trading volume on Monday . 357,221 shares traded hands during trading, an increase of 1% from the previous session’s volume of 352,706 shares.The stock last traded at $6.52 and had previously closed at $6.34.

Several brokerages have commented on OVAS. Leerink Swann reissued a “hold” rating and set a $7.00 price objective (up previously from $6.00) on shares of OvaScience in a research report on Sunday, May 8th. JPMorgan Chase & Co. reduced their price target on OvaScience from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Friday, August 5th. JMP Securities restated a “neutral” rating on shares of OvaScience in a report on Wednesday, August 10th. Zacks Investment Research upgraded OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a report on Wednesday, August 10th. Finally, Oppenheimer Holdings Inc. restated a “hold” rating on shares of OvaScience in a report on Monday, April 25th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $10.98.

The firm’s market capitalization is $213.01 million. The company has a 50 day moving average of $5.52 and a 200-day moving average of $7.07.

OvaScience (NASDAQ:OVAS) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.62) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. During the same period last year, the company earned ($0.64) EPS. The business earned $0.19 million during the quarter, compared to the consensus estimate of $0.21 million. The business’s revenue was up 530.0% compared to the same quarter last year. Analysts predict that OvaScience Inc. will post ($2.66) earnings per share for the current fiscal year.

In other OvaScience news, CEO Michelle Dipp acquired 425,000 shares of the business’s stock in a transaction on Wednesday, June 1st. The shares were bought at an average price of $7.00 per share, with a total value of $2,975,000.00. Following the transaction, the chief executive officer now directly owns 971,921 shares of the company’s stock, valued at approximately $6,803,447. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.